<DOC>
	<DOCNO>NCT03005678</DOCNO>
	<brief_summary>A randomize control trial compare efficacy tolerability denosumab oral alendronate management glucocorticoid induce osteoporosis</brief_summary>
	<brief_title>Denosumab Versus Bisphosphonates ( Alendronate ) GIOP</brief_title>
	<detailed_description>Study design : open-label randomized control trial Duration study : 12 month Treatment arm : 1 . Denosumab : total 2 dos period 12 month 2 . Oral alendronate : weekly dose period 12 month Target sample size : 220 patient ( 110 patient arm )</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>1 . Adults ( woman men ) &gt; 18 year age 2 . Receiving longterm prednisolone treatment various medical illness , define daily prednisolone dose ≥2.5mg/day ≥12 month ) . 3 . Informed consent patient . 4 . Willing comply study procedures 1 . Patients previous use denosumab , teriparatide , intravenous bisphosphonates , strontium experimental antiosteoporotic agent . 2 . Premenopausal woman plan pregnancy within 18 month study entry . 3 . Patients know bone disorder osteomalacia , renal osteodystrophy , hyperparathyroidism . 4 . Patients unexplained hypocalcemia . 5 . Patients serum creatinine level &gt; =200umol/L .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>glucocorticoid , steroid , osteoporosis</keyword>
</DOC>